Efficacy of a canarypox virus-vectored vaccine against feline leukaemia

@article{Poulet2003EfficacyOA,
  title={Efficacy of a canarypox virus-vectored vaccine against feline leukaemia},
  author={Herv{\'e} Poulet and Sylvie Brunet and C Boularand and A. L. Guiot and Vincent Leroy and James Tartaglia and Jules Maarten Minke and Jean Christophe Franc Audonnet and Ph. Desmettre},
  journal={Veterinary Record},
  year={2003},
  volume={153},
  pages={141 - 145}
}
Canarypox virus recombinant vaccines have a unique efficacy and safety profile for the vaccinated host because the canarypox virus is non-replicative in mammalian hosts. After the vaccination of a mammalian species, recombinant canarypox viruses express the inserted genes but cannot multiply in the host. They stimulate a strong immune response in the absence of any virus amplification in the host or any viral spread into the environment. A new canarypox-based recombinant vaccine is the… 
A Comparative Study of the Efficacy of a Canarypox Based Recombinant Leukemia Vaccine against a Natural Contact Felv Challenge in Cats
TLDR
The natural contact challenge model proved to be a potent method to reproduce FeLV challenge, confirming that under appropriate conditions FeLV is efficiently transmitted.
No benefit of therapeutic vaccination in clinically healthy cats persistently infected with feline leukemia virus.
TLDR
It is concluded that vaccinating persistently FeLV-infected cats cannot be recommended as a means of improving their FeLV status, quality of life or life expectancy, and it is suggested to testing of all cats for FeLV infection prior to FeLV vaccination.
Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors
TLDR
It is hoped that this body of data will contribute to a better understanding of the relevance of specific immunogenicity end points to protection and the predictive value of available animal models in HIV vaccine development.
Reassessment of feline leukaemia virus (FeLV) vaccines with novel sensitive molecular assays.
TLDR
All cats vaccinated with either a canarypox-vectored live or a killed virus vaccine were found to be plasma viral RNA positive and the loads were significantly associated with the infection outcome.
- 1-No benefit of therapeutic vaccination in clinically 1 healthy cats persistently infected with feline leukemia 2 virus 3 4
Therapeutic vaccinations have a potential application in infections where no curative treatment is available. In contrast to HIV, efficacious vaccines for a cat retrovirus, feline leukemia virus
Novel Approaches for Vaccination against Equine Viral Arteritis
TLDR
The rational for using a sub-unit adjuvanted vaccine and a recombinant live virus vaccine, analysis of immune responses they induce and assessment of the protection against infection in experimental conditions is described and discussed in this thesis.
Protection from challenge following administration of a canarypox virus-vectored recombinant feline leukemia virus vaccine in cats previously vaccinated with a killed virus vaccine.
TLDR
Protection against FeLV challenge obtained after administration of 2 doses of an adjuvanted, chemically inactivated, whole FeLV (FeLV-k) vaccine with protection obtained following administration of 1 dose of an FeLV- k vaccine followed by a canarypox virus-vectored recombinantFeLV (rCP-FeLV) vaccine is suggested.
The Evolution of Poxvirus Vaccines
TLDR
This review highlights the evolution of poxvirus vaccines, from first generation to the current status, pointing out how different vaccines have emerged and approaches that are being followed up in the development of more rational vaccines against a wide range of diseases.
Comparative Efficacy of Feline Leukemia Virus (FeLV) Inactivated Whole-Virus Vaccine and Canarypox Virus-Vectored Vaccine during Virulent FeLV Challenge and Immunosuppression
TLDR
It is demonstrated that Nobivac feline 2-FeLV-vaccinated cats were fully protected against persistent antigenemia and had significantly smaller amounts of proviral DNA and plasma viral RNA loads than PureVax recombinant FeLV- vaccinated cats and unvaccinated controls.
Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep.
TLDR
It is confirmed that the BTV-CP vaccine may be useful for the protective immunization of ruminants against bluetongue, and it may avoid the problems inherent to live-attenuated (LA) BTV vaccines.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 25 REFERENCES
Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL
TLDR
These results represent the first effective vaccination of cats against FeLV with a poxvirus-based recombinant vector and have implications that are relevant not only to FeLV vaccine development but also to developing vaccines against other retroviruses, including human immunodeficiency virus.
Comparative studies of the efficacy of a recombinant feline leukaemia virus vaccine
TLDR
Results indicate that a recombinant vaccine, containing only the protein moiety of the surface glycoprotein of FeLV-A, can provide better protection than the inactivated virus vaccines tested against challenge with virus of the same subgroup, and can also protect against challenge by all three subgroups of Fe LV.
The safety and use of canarypox vectored vaccines.
TLDR
Canarypox recombinants effectively prime the immune system for induction of antibodies and CD8 cell-mediated cytotoxicity by protein antigens, and are immunogenic by the intramuscular and subcutaneous routes.
Vaccination against feline leukaemia using a new feline herpesvirus type 1 vector.
TLDR
A recombinant feline herpesvirus type 1 (FHV-1) was constructed expressing the envelope glycoprotein gene from feline leukaemia virus (FeLV) to protect against FeLV compared with previous reports using live recombinant vaccines.
Feline leukaemia virus: a review of immunity and vaccination.
  • A. Sparkes
  • Medicine
    The Journal of small animal practice
  • 1997
TLDR
The role of the immune response in determining the outcome following exposure to FeLV and the importance of FeLV subgroups is described and the published literature on efficacy studies is summarized.
Feline leukaemia virus: protective immunity is mediated by virus‐specific cytotoxic T lymphocytes
TLDR
This is the first report highlighting the very significant role that virus‐specific CTL have in determining the outcome of FeLV infection in either vaccinated cats or cats recovering naturally from FeLV exposure.
Recombinant Canarypox Vaccine-Elicited CTL Specific for Dominant and Subdominant Simian Immunodeficiency Virus Epitopes in Rhesus Monkeys1
TLDR
The temporal association of the emergence of the dominant epitope-specific response with early viral containment following challenge suggests that this immune response played a role in the accelerated clearing of early viremia in rhesus monkeys.
Passive immunity to feline leukemia: evaluation of immunity from dams naturally infected and experimentally vaccinated
TLDR
In an attempt to induce protective maternal antibody by vaccination, 10 pregnant cats were immunized by three to five weekly intramuscular injections with purified FeLV inactivated by ultraviolet irradiation, but neither virus-neutralizing nor FOCMA antibody was detectable in the dams or in 19 kittens born to these cats.
Longitudinal Analysis of Feline Leukemia Virus-Specific Cytotoxic T Lymphocytes: Correlation with Recovery from Infection
TLDR
An important role is suggested for FeLV-specific CTLs in retroviral immunity and the potential to modulate disease outcome by the adoptive transfer of antigen-specific T cells in vivo is demonstrated.
Reactivation of latent feline leukaemia virus infection
TLDR
The reactivation of latent FeLV from myelomonocytic and lymphoid cells of cats immune to FeLV, cats bearing FeLV-negative tumours, and kittens congenitally exposed toFeLV is described.
...
1
2
3
...